The son of Lebanon, Dr. Jawad Youssef Fares, received the King Hussein Prize for Cancer Research for the year 2022, which is an award for an emerging researcher in the international track.

Dr. Fares has multiple publications in high impact journals such as Translational Medicine of Sciences and most recently in The Lancet Oncology. His first paper, in The Lancet Oncology, described the first use in humans of neural stem cells to deliver an implicated adenovirus in newly diagnosed patients with glioma, Dr. Fares continues his research at an American university. The King Hussein Award for Cancer Research was launched in the year 2020, to enhance research efforts related to cancer in the Arab world and to commemorate the late Jordanian King Hussein bin Talal, who has always believed in the importance of cancer research. The award honors distinguished Arab researchers in the research field. Whether they are researchers with long experience, or promising ones.

The award aims to raise the level of Arab research and development, in order to understand the characteristics of cancer in the Arab region, and to study Arab genes in particular, so that we can confront the disease and overcome it by advanced scientific methods.

Prince Talal bin Muhammad, representing King Abdullah II of Jordan, honored the winning researchers of the Hussein Prize for Cancer Research for the year 2022, at a ceremony organized by the King Hussein Cancer Foundation in the Jordanian capital, Amman, In the presence of the Chairperson of the Board of Trustees of the King Hussein Cancer Foundation and Center, Princess Ghida Talal and Princess Sumaya bint El Hassan. Prince Talal bin Muhammad handed shields to seven winners from Jordan, the United Arab Emirates, Lebanon and the United States of America out of 137 advanced researchers from 16 countries, as all participants underwent an evaluation by a specialized arbitration committee for each category based on the criteria of the award specified by category Submission